Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions

Author(s): Carmen Cerchia, Antonio Lavecchia*

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 21 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Malignant melanoma is the most aggressive and life-threatening skin cancer. Melanoma develops in melanocytes and is characterized by a very high tendency to spread to other parts of the body. Its pathogenesis depends on DNA mutations leading to the activation of oncogenes or to the inactivation of suppressor genes. The identification of misregulations in intracellular signal transduction pathways has provided an opportunity for the development of mutation-specific inhibitors, which specifically target the mutated signaling cascades. Over the last few years, clinical trials with MAPK pathway inhibitors have shown significant clinical activity in melanoma; however, their efficacy is limited due to the onset of acquired resistance. This has prompted a large set of preclinical studies looking at new approaches of pathway- or target-specific inhibitors. This review gives an overview of the latest developments of small molecule targeting multiple molecular pathways in both preclinical and clinical melanoma settings, with particular emphasis on additional strategies to tackle the reduced responsiveness to inhibitor treatment as possible future directions.

Keywords: Melanoma, metastasis, small molecules, targeted therapies, drug-resistance, MAPK pathway, cell cycle control.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 23 August, 2017
Page: [2312 - 2344]
Pages: 33
DOI: 10.2174/0929867324666170414163937
Price: $65

Article Metrics

PDF: 54
HTML: 11
PRC: 1